Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protalix BioTherapeutics, Inc. (DE) Common Stock (NY:PLX)

1.370 -0.030 (-2.14%)
Streaming Delayed Price Updated: 9:44 AM EDT, Jun 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protalix BioTherapeutics, Inc. (DE) Common Stock

< Previous 1 2 3 4 Next >
Top movers in Friday's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
The market is filled with gapping stocks in Friday's session.
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Earnings Outlook For Protalix BioTherapeutics
Via Benzinga
Earnings Preview: Protalix BioTherapeutics
Via Benzinga
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Earnings Preview For Protalix BioTherapeutics
Via Benzinga
Wondering what's happening in today's pre-market session?
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Earnings Scheduled For May 9, 2025
Via Benzinga
Preview: Protalix BioTherapeutics's Earnings
Via Benzinga
Uncovering Potential: Protalix BioTherapeutics's Earnings Preview
Via Benzinga
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
Via Stocktwits
Topics Stocks
Exposures US Equities
Evaluating PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) using Mark Minervini’s winning stock formula
A fundamental and technical analysis of (NYSEARCA:PLX): PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) may be suited for high growth investing, we'll explore why in this article. 
Via Chartmill
Does PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) show the characteristics of a Minervini super stock?
A fundamental and technical analysis of (NYSEARCA:PLX): Is PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) suited for high growth investing? 
Via Chartmill
iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025
Via ACCESS Newswire
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025. 
Via Benzinga
Earnings Scheduled For March 17, 2025
Via Benzinga
Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
Earnings Scheduled For November 14, 2024
Via Benzinga
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024
PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024
PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
Pullix Gains Momentum As Gamestop Exits NFT Space
Notable NFT news this week is from video game retailer GameStop, which has announced its NFT marketplace will shut down next month. The publicly-traded company is citing “regulatory uncertainty” for... 
Via Talk Markets
Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.